RotaTeq is a live, oral pentavalent vaccine that contains 5 reassortant viruses.
Four reassortant rotaviruses express one of the outer capsid proteins (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (serotype P7) from the bovine rotavirus parent strain.
The fifth reassortant virus expresses the attachment protein, P1A (genotype P), herein referred to as serotype P1A, from the human rotavirus parent strain and the outer capsid protein of serotype G6 from the bovine rotavirus parent strain.
RotaTeq was extensively tested and was approved by the US Food and Drug Administration (FDA) in February 2006.
RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9.
RotaTeq is approved for use in infants 6 weeks to 32 weeks of age.
The vaccination series is administered as an oral 3-dose series to infants between the ages of 6 to 32 weeks.
The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
The third dose should not be given after 32 weeks of age.
April 29, 2021 - Merck reported RotaTeq vaccine sales decreased 29% last year.
RotaTeq Clinical Trials
RotaTeq was US FDA approved in 2006. This rotavirus vaccine continues to be challenged in clinical trials today.